|
|
|
| Association of Serum CAR LMR and T Lymphocyte Subsets with Prognosis of Multiple Myeloma Patients |
| DA Haili, ZHANG Xuguang, et al |
| Fenyang Hospital, Shanxi Fenyang 032200, China |
|
|
|
|
Abstract Objective: To investigate the association of serum C-reactive protein to albumin ratio (CAR), lymphocyte to monocyte ratio (LMR), and T lymphocyte subsets with the prognosis of multiple myeloma (MM) patients. Methods: A total of 105 patients with multiple myeloma diagnosed and treated from January 2020 to January 2022 were selected as the study objects and set as the observation group. A total of 75 healthy controls were enrolled as the control group. MM patients were divided into poor prognosis group (n=34) and good prognosis group (n=71) according to whether recurrence or death occurred within 2 years of follow-up after treatment. Serum CAR, LMR, and T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) were compared. Logistic regression analysis was used to analyze the effects of CAR, LMR, CD3+, CD4+, CD8+ and CD4+/CD8+ on the prognosis of MM patients. ROC curve analysis was used to analyze the AUC values, sensitivity, and specificity of CAR, LMR, CD3+, CD4+, CD8+, CD4+/CD8+ and T lymphocyte subsets to predict the prognosis of MM patients. Results: The CAR and CD8+ levels were significantly higher, while the LMR, CD3+, CD4+, and CD4+/CD8+ levels were significantly lower in the observation group than in the control group (P<0.05). The CAR and CD8+ levels were significantly higher, while the LMR, CD3+, CD4+, and CD4+/CD8+ levels were significantly lower in the poor prognosis group than in the good prognosis group (P<0.05). Binary Logistic regression model analysis showed that the increase of CAR and CD8+ and the decrease of LMR, CD3+, CD4+, CD4+/CD8+ would affect the prognosis of MM patients (P<0.05). ROC curve analysis showed that the combined parameters of CAR, LMR, CD3+, CD4+, CD8+, CD4+/CD8+ and T lymphocyte subsets predicted the prognosis of MM patients with AUC values of 0.637, 0.792, 0.726, 0.767, 0.669, 0.750, 0.853, respectively (P<0.05). Conclusion: Serum CAR, LMR, and T lymphocyte subsets showed abnormal expression trends in MM patients. The detection of their changes is helpful for providing important reference for the assessment of the prognosis of MM patients.
|
|
|
|
|
|
[1] 王碧薇,孙辉,陈曦,等.硼替佐米联合来那度胺治疗多发性骨髓瘤的临床疗效[J].中国老年学杂志,2022,42(9):2097-2099.
[2] Lonial S,Lee HC,Badros A,et al.Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma:13-month follow-up from the pivotal DREAMM-2 study[J].Cancer,2021,127(22):4198-4212.
[3] 陈明真,张学亚,王美娥,等.多发性骨髓瘤患者血脂指标水平及预后意义[J].中国实验血液学杂志,2022,30(4):1162-1169.
[4] 胡俊泽,谢权,马建伟,等.食管癌患者血清NLR LMR NMR与预后的关系研究[J].河北医学,2023,29(2):254-259.
[5] 余延芳,高乃姝,王明迪,等.多发性骨髓瘤患者外周血淋巴细胞亚群动态变化的临床意义[J].中国肿瘤临床与康复,2021,28(6):660-663.
[6] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020,59(5):341-346.
[7] 王腾,王晓晨,吕纯懿,等.嵌合抗原受体T淋巴细胞治疗多发性骨髓瘤疗效及安全性的Meta分析[J].中国全科医学,2021,24(2):219-224,231.
[8] 况小红,童浩,代明辉,等.多发性骨髓瘤组织CTGF表达变化及其与患者临床病理特征和预后的关系[J].山东医药,2021,61(10):36-40.
[9] 苏传勇,陶叠宏,任莉,等.多发性骨髓瘤患者外周血NLR水平与T淋巴细胞亚群的相关性及对预后的影响[J].中华全科医学,2022,20(2):209-211,232.
[10] 安然,陈钰,张苏江,等.免疫炎性指标和淋巴细胞亚群在初诊多发性骨髓瘤预后判断中的意义[J].临床血液学杂志,2022,35(3):168-173. |
|
|
|
2024, Vol. 30 
